Levosimendán Accord (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, which strengthens heart‑muscle contraction without raising intracellular calcium levels. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous dilation that lowers preload and afterload, supporting overall cardiac performance.

The dosing regimen for Levosimendán Accord is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals set the infusion rate and duration according to established guidelines and individual therapeutic goals.

Safety data for levosimendan during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Levosimendan differs from traditional inotropes such as dobutamine by increasing contractility through calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of calcium‑overload arrhythmias. It also provides vasodilation via potassium‑channel activation, whereas dobutamine primarily increases heart rate and may cause more tachycardia.

Levosimendán Accord should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. The product must be kept in a secure, dry area and handled according to standard aseptic techniques for intravenous preparations.

Levosimendán Accord is given by intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion over 24 hours. Administration is performed under close clinical monitoring of hemodynamic parameters, and the infusion set must be compatible with the drug’s formulation.

Serious adverse events include life‑threatening arrhythmias, severe hypotension, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored continuously for cardiac rhythm changes, blood‑pressure drops, and signs of ischemic chest pain throughout the infusion.

Levosimendán Accord is contraindicated in patients with known hypersensitivity to levosimendan or any excipients, those with severe hypotension (systolic blood pressure < 90 mmHg), and individuals with significant obstructive cardiac outflow lesions. Caution is also advised in patients with severe hepatic or renal impairment.